Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Desiree Norman

Nurse Practitioner, Psychiatric/Mental Health Gulfport, MS Nurse Practitioner

NPI 1861898355 CMS profile 10621421

11150 Highway 49, Mbh Outpatient Clinic, Gulfport, MS 39503

Open in the dashboard

General payments

$9,915

574 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Desiree Norman of Gulfport, MS is reported in the CMS Open Payments database as having received $9,915 across 574 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,133 109
2024 General $2,299 126
2023 General $2,394 149
2022 General $1,593 101
2021 General $1,497 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Desiree Norman
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Desiree Norman were reported at $2,133. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Desiree Norman Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,497 $166 $54–$482 $132
2022 $1,593 $195 $66–$559 $149
2023 $2,394 $233 $82–$673 $160
2024 $2,299 $236 $84–$688 $164
2025 $2,133 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $1,586 87 payments
  2. Tris Pharma Inc $1,422 100 payments
  3. Noven Therapeutics, LLC $1,399 85 payments
  4. AbbVie, Inc. $900 60 payments
  5. ITI, Inc. $734 38 payments
  6. Ironshore Pharmaceuticals Inc. $620 32 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $523 25 payments
  8. Corium, Inc. $430 23 payments
  9. Axsome Therapeutics, Inc. $430 23 payments
  10. Collegium Pharmaceutical, Inc. $391 19 payments
  11. Other $1,479 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,912 573 payments
  2. Education $3 1 payment
Products named General payments · program years 2021–2025
  1. Xelstrym $1,369 82 payments
  2. Dyanavel XR $956 79 payments
  3. QELBREE Psychology $877 64 payments
  4. VRAYLAR $715 50 payments
  5. Qelbree Viloxazine Hydrochloride $709 23 payments
  6. CAPLYTA $493 26 payments
  7. Azstarys $430 23 payments
  8. Auvelity $430 23 payments
  9. Jornay PM Adhd $391 19 payments
  10. JORNAY PM Central Nervous System Stimulant $319 15 payments
  11. Other $3,453 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

38

Median for Nurse Practitioner: 389

Drug cost

$6,486

Median for Nurse Practitioner: $21,885

Branded share of claims

100%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dyanavel Xr Amphetamine Brand 12 $5,032
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 11 $1,307
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $147

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xelstrym
  • Noven Therapeutics, LLC $491
  • Noven Pharmaceuticals, Inc. $24
$515 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $460
$460 — —
Auvelity
  • Axsome Therapeutics, Inc. $237
$237 — —
CAPLYTA
  • ITI, Inc. $183
$183 — —
Azstarys
  • Corium, Inc. $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

574 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record